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ventricular hypertrophy (LVH) develops as an adaptive response to sarcomere dysfunction. It remains unclear whether
persistent expression of the mutant gene is required for LVH or whether early gene expression acts as an immutable
inductive trigger.
OBJECTIVES The aim of this study was to use a regulatable murine model of HCM to study the reversibility of
pathological LVH.
METHODS The authors generated a double-transgenic mouse model, tTA x aMHCR403Q, in which expression of the
HCM-causing Arg403Gln mutation in the a-myosin heavy chain (MHC) gene is inhibited by doxycycline administration.
Cardiac structure and function were evaluated in groups of mice that received doxycycline for varying periods from 0 to
40 weeks of age.
RESULTS Untreated tTA x aMHCR403Q mice showed increased left ventricular (LV) mass, contractile dysfunction,
myoﬁbrillar disarray, and ﬁbrosis. In contrast, mice treated with doxycycline from conception to 6 weeks had markedly
less LVH and ﬁbrosis at 40 weeks. Transgene inhibition from 6 weeks reduced ﬁbrosis but did not prevent LVH or
functional changes. There were no differences in LV parameters at 40 weeks between mice with transgene inhibition
from 20 weeks and mice with continuous transgene expression.
CONCLUSIONS These ﬁndings highlight the critical role of the early postnatal period in HCM pathogenesis and
suggest that mutant sarcomeres manifest irreversible cardiomyocyte defects that induce LVH. In HCM, mutation-silencing
therapies are likely to be ineffective for hypertrophy regression and would have to be administered very early in life
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ABBR EV I A T I ON S
AND ACRONYMS
CVF = collagen volume fraction
DCM = dilated cardiomyopathy
HCM = hypertrophic
cardiomyopathy
LV = left ventricular
LVDD = left ventricular
end-diastolic diameter
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561H ypertrophic cardiomyopathy (HCM) is a her-itable myocardial disorder associated withan increased risk of congestive heart failure,
myocardial ischemia, cardiac arrhythmias, and sudden
death, particularly in young individuals (1,2). Given the
substantial morbidity and mortality of HCM, discov-
ering strategies that induce regression or prevent left
ventricular hypertrophy (LVH) would have substantial
clinical impact.SEE PAGE 570 LVFS = left ventricular
fractional shortening
LVH = left ventricular
hypertrophy
MHC = myosin heavy chain
RNAi = ribonucleic
acid interference
tTA = tetracycline
transactivator
WT = wild-typeThe contemporary mechanistic paradigm for HCM
is that primary perturbations of sarcomere function
resulting from disease gene mutations trigger a
cascade of cardiomyocyte responses including
changes in calcium homeostasis, energy use, and
gene expression that culminate in the hallmark
pathological features of myocardial hypertrophy,
disarray, and ﬁbrosis (1,2). Although numerous in-
terventions that modify downstream hypertrophic
pathways have been evaluated, the effects of ther-
apies that primarily inactivate or interfere with
expression of mutant HCM genes have not been
fully explored.
The ﬁrst mutation discovered to have an associa-
tion with HCMwas an Arg403Gln substitution in the b-
myosin heavy chain (MHC) gene (3), and this mutation
has been studied in murine and rabbit models (4–10).
The 2 isoforms of cardiac MHC, a and b, vary in
expression among species and developmental stages
(11). In humans and rabbits, b is the major isoform in
the normal adult ventricle. In mice, there is a post-
natal isoform switch from b to a, and thus human
b mutations are typically modeled in the murine
a gene. The ﬁrst Arg403Gln a-MHC model was
generated using a “hit-and-run” approach (4).
Heterozygous mice developed HCM during adult life,
whereas their homozygous littermates showed
fulminant dilated cardiomyopathy (DCM) and died
during the ﬁrst postnatal week (4–6). In a seminal
study, Jiang et al. (12) reported that ribonucleic acid
interference (RNAi)–induced silencing of the mutant
allele in heterozygous mice suppressed the develop-
ment of HCM only when silencing was induced in mice
at 1 day of age, with no effect on mice with overt HCM.
Here we report a novel regulatable mouse model of
HCM in which mice carrying an Arg403Gln a-MHC
transgene under the control of a tetracycline operon
were crossed to mice that carried a tetracycline trans-
activator (tTA) transgene under the control of the
a-MHC promoter (13). In the double-transgenic mice,
tTA x a-MHCR403Q, Arg403Gln is constitutively ex-
pressed but can be inhibited by adding the tetracycline
analogue, doxycycline, to drinkingwater.We used thismodel to determine whether transgene inhi-
bition at varying times in adult mice would
enable HCM to be reversed or prevented. Our
data support the use of mutation-silencing
strategies for primary prevention of HCM but
suggest that there is a limited time window
in which such therapies are likely to be
effective.
METHODS
ANIMAL MODEL. A construct containing
murine Myh6 complementary deoxyribon-
ucleic acid (cDNA) with the Arg403Gln mu-
tation and a Kozak consensus sequence
(accAUGg) was cloned into a pTet splice
plasmid vector downstream of 7 copies of the
tetracycline operator and a single copy of the
human cytomegalovirus (CMV) minimal pro-
moter (Figure 1A). DNA was injected into
pronuclei of zygotes from FVB/N mice, and transgenic
mice were generated and maintained on an FVB/N
background. Heterozygous carriers of the Arg403Gln
a-MHC (aMHCR403Q) transgene were then crossed to
mice carrying a single tTA transgene under the con-
trol of the a-MHC promoter on an FVB/N background
(Jackson Laboratory, Bar Harbor, Maine) (13) to pro-
duce double-transgenic offspring (referred to as tTA x
aMHCR403Q). Expression of the aMHCR403Q transgene
was turned off by administering 1 mg/ml doxycycline
mixed with 25 mg/ml sucrose in mouse drinking
water. Wild-type (WT) controls were littermates of
tTA x aMHCR403Q mice that did not carry either the
aMHCR403Q or tTA transgenes. Mice were genotyped
by polymerase chain reaction (PCR) ampliﬁcation of
tail genomic DNA and were maintained and evaluated
according to protocols approved by the Garvan-St
Vincent’s Hospital Animal Ethics Committee (Dar-
linghurst, Australia).
ECHOCARDIOGRAPHY. Mice were sedated with 2.5%
tribromoethanol (Avertin), 0.005 to 0.01 ml/g) by
intraperitoneal injection, and transthoracic echocar-
diography was performed using a Sonos 5500 ultra-
sonograph (Philips Medical Systems, Andover,
Massachusetts) and a 12- to 15-mHz probe. Heart rate
was monitored by continuous electrocardiography.
MYOCARDIAL HISTOPATHOLOGY. Hearts were dis-
sected, washed in 0.9% sodium chloride, ﬁxed in 4%
paraformaldehyde overnight, dehydrated in 70%
ethanol, and embedded in parafﬁn. Tissue blocks
were cut into 3-mm sections, placed on glass slides,
and stained with hematoxylin and eosin or picrosirius
red. Sections were reviewed by an independent
FIGURE 1 Generation of Regulatable tTA x aMHCR403Q Mice
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(A) Construct design used to generate double-transgenic tetracycline transactivator (tTA) x a-myosin heavy chain (MHC)R403Q mice. (B) Polymerase chain reaction (PCR)
of left ventricular (LV) genomic deoxyribonucleic acid demonstrating presence of the transgenes, aMHCR403Q (1095 bp product) and tTA (300 bp product) in single- and
double-transgenic mice. (C) Real-time PCR (RT-PCR) showing expression of aMHCR403Q transcript in the heart (H), but not in gastrocnemius skeletal muscle (Sk) or
bladder smooth muscle (Sm). (D) RT-PCR showing expression of the aMHCR403Q transgene in LV tissue from 12-week-old male tTA x aMHCR403Q mice treated with
vehicle or doxycycline (dox) post-weaning (n ¼ 3 each group). (E)Western blot showing levels of Q403 a-MHC and R403 a-MHC protein in 12-week-old male wild-type
(WT) mice, untreated tTA x aMHCR403Q mice, and dox-treated tTA x aMHCR403Q mice. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading
control. (F) Mean levels of Q403 a-MHC (left panel) and R403 a-MHC (right panel) normalized to GAPDH in WT mice (n ¼ 4, blue bars), untreated tTA x aMHCR403Q
mice (n ¼ 6, salmon bars), and dox-treated tTA x aMHCR403Q mice (n ¼ 6, grey bars). *p < 0.05, ***p < 0.001; analysis of variance (ANOVA) and Student t test.
CMVmin ¼ CMV minimal promoter; (tetO)7, 7 copies of the tetracycline operator; Poly-A, polyadenylated tail.
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562cardiac histopathologist for the presence of myoﬁ-
brillar disarray. Interstitial ﬁbrosis was quantitatively
estimated by collagen volume fraction (CVF), deﬁned
as the number of picrosirius red–positive pixels to the
total number of pixels in each ﬁeld (ImageJ software,
National Institutes of Health, Bethesda, Maryland).
Ten random ﬁelds were evaluated for each mouse.
For electron microscopy, hearts were ﬁxed in 2.5%
glutaraldehyde, 0.1 mol/l sodium cacodylate buffer,
washed, post-ﬁxed with 2% osmium tetroxide and 2%
uranyl acetate solution, dehydrated in ethanol, and
embedded in epoxy resin. Sections were viewed using
a JEM-1400 transmission electron microscope (Jeol,Peabody, Massachusetts) at 3,500 magniﬁcation.
Z-disc alignment was assessed using ImageJ software
by measuring the longitudinal distance from a per-
pendicular line drawn across neighboring myoﬁbrils
(14). A minimum of 25 measurements from 10 ﬁelds in
each mouse was made.
RNA PREPARATION AND QUANTITATIVE PCR. Total
RNA was extracted from left ventricular (LV) tissue,
and cDNA was synthesized using the SuperScript
III First Strand Synthesis SuperMix Kit (Invitrogen,
Carlsbad, California) for real-time quantitative PCR,
which was performed on a LightCycler480 thermal
cycler (Roche, Basel, Switzerland). Gene expression
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563levels were normalized to reference genes Hprt1
and Ppia.
ANTIBODY SYNTHESIS. To identify Q403 mutant
myosin, a custom polyclonal a-MHC antibody was
synthesized (Peptide Specialty Laboratories, Heidel-
berg, Germany). WT and mutant peptides were
generated that comprised 15 amino acids in the
vicinity of residue 403 in murine a-MHC. The
WT peptide contained an R at residue 403
(LKGLXHPRVKVGNEY), and the mutant peptide had a
Q at this site (LKGLXHPQVKVGNEY).
WESTERN BLOTTING. Total protein was extracted
from LV tissue, separated on a 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis gel, and
incubated with puriﬁed polyclonal Q403 a-MHC
antibody (1:1,000 dilution) or speciﬁc antibodies
against R403 a-MHC (1:2,500 dilution; Santa Cruz
Biotechnology, Inc., Dallas, Texas) and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (1:2,000
dilution; Abcam, Cambridge, United Kingdom), with
antimouse, antigoat, and antirabbit horseradish
peroxidase–conjugated secondary antibodies, res-
pectively (Abcam). Hybridization signals were quan-
tiﬁed and normalized to GAPDH.
STATISTICAL ANALYSIS. Differences among groups
were assessed using analysis of variance and Stu-
dent t test. Data are expressed as mean  SD;
p values <0.05 were considered statistically sig-
niﬁcant, with no adjustments made for multiple
comparisons.
RESULTS
GENERATION OF DOUBLE-TRANSGENIC MICE .
Heterozygous mice bearing the aMHCR403Q or
tTA transgenes were crossed to produce double-
transgenic (tTA x aMHCR403Q) offspring (Figures 1A
and 1B). The tTA x aMHCR403Q mice were viable and
phenotypically normal at birth. Real-time PCR
showed cardiac-speciﬁc expression of the aMHCR403Q
transgene (Figure 1C) in LV samples from tTA x
aMHCR403Q mice, and signiﬁcant reductions of
mutant a-MHC transcript were induced by doxycy-
cline (Figure 1D). Presence of Q403 a-MHC protein in
tTA x aMHCR403Q mice was demonstrated by Western
blotting using a mutation-speciﬁc antibody (Figure 1E,
top panel; weak cross-reaction of this antibody
occurred with the WT R403 protein; see WT lanes). In
contrast to the levels of R403 protein, which were
similar in WT and tTA x aMHCR403Q mice and un-
changed after doxycycline treatment, levels of Q403
a-MHC were markedly reduced by doxycycline
(Figures 1E and 1F).CARDIAC PHENOTYPE ANALYSIS. Cardiac mor-
phology and function were evaluated in 6-, 12-, 20-,
and 40-week-old tTA x aMHCR403Q mice and in WT
littermates. Both groups had similar low rates of
mortality (5%). Male tTA x aMHCR403Q mice showed
increased heart weight/body weight ratio and echo-
cardiographically derived LV mass (Figure 2A to 2C),
as well as increased mean LV end-diastolic diameter
(LVDD) and left atrial diameter (LAD) and reductions
in LV fractional shortening (LVFS) (Figure 2D to 2F,
Online Table 1). Female tTA x aMHCR403Q mice showed
similar but less severe morphological and functional
changes (Online Figures 1A to 1H, Online Table 2).
Light microscopy of LV sections stained with
hematoxylin and eosin showed myoﬁbrillar disarray
in all 4 male tTA x aMHCR403Q mice and in 2 of 3
female tTA x aMHCR403Q mice evaluated at 40 weeks,
but in none of 6 WT mice (3 male, 3 female)
(Figure 2G). Assessment of LV ﬁbrosis by collagen-
speciﬁc picrosirius red staining showed that
40-week-old male tTA x aMHCR403Q mice had a
signiﬁcantly higher CVF than WT mice (WT, n ¼ 6, 1.6
 1.3%, versus tTA x aMHCR403Q, n ¼ 6, 3.3  2.4%;
p < 0.001; Figure 2H). There were no differences in
CVF between female WT and tTA x aMHCR403Q mice
(WT, n ¼ 3, 1.3  0.6 % versus tTA x aMHCR403Q, n ¼ 3,
1.5  0.6%; p ¼ 0.35). On electron microscopy, tTA x
aMHCR403Q mice showed misalignment of Z-discs
in adjacent myoﬁbrils (mean displacement, 200 
204 nm) when compared with WT mice (119  82 nm;
p < 0.001; Online Figure 2).
To determine whether the presence of the tTA
transgene could have independent phenotype-
modifying effects, male tTA mice were evaluated
(Online Figures 3A to 3G). There were modest differ-
ences in heart weight/body weight ratio and LV mass
between tTA mice and male WT mice at 40 weeks.
When male tTA x aMHCR403Q mice and tTA mice were
compared, however, there were substantially greater
differences in heart weight/body weight ratio, LV
mass, LVDD, LVFS, and LAD, similar to comparisons
between WT and tTA x aMHCR403Q mice. LV sections
from tTA mouse hearts showed no myocardial
disarray, and CVF was similar to that in WT mice.
aMHCR403Q TRANSGENE SUPPRESSION AT VARYING
AGES. To determine whether inhibition of aMHCR403Q
transgene expression would prevent or induce re-
gression of LVH, male WT and tTA x aMHCR403Q mice
were given oral doxycycline or vehicle (25 mg/ml
sucrose) from 6 weeks (D6-40, early disease) or
20 weeks (D20-40, established disease) and were
evaluated at 40 weeks of age. In the early disease
group, there were no differences in indices of LVH
FIGURE 2 Cardiac Phenotype of Male tTA x aMHCR403Q Mice
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564or LV function between doxycycline-treated and
vehicle-treated tTA x aMHCR403Q mice (Figures 3A
to 3H, Online Table 3). Transgene inhibition from
6 weeks did not prevent myoﬁbrillar disarray, but
it did reduce the CVF. Transgene inhibition from
20 weeks in the established disease group produced
no effects on any LV functional or histopathological
parameters (Figure 3, Online Table 4). The lack of LVH
prevention or regression was not the result of any
pro-hypertrophic actions of doxycycline because
there were no signiﬁcant effects of drug treatment in
WT mice or in tTA mice (Figure 3, Online Figure 4).These observations suggest that the pathological
processes that promote LVH in tTA x aMHCR403Q mice
are set in place very early in life, and removal of
the genetic trigger after 6 weeks cannot prevent or
reverse these processes. To investigate the effects
of transgene exposure during cardiac development
further, a third group of male WT and tTA x
aMHCR403Q mice was treated with doxycycline from
conception to 6 weeks of age (D0-6) and then evalu-
ated at 40 weeks of age. When compared with the
previous groups of tTA x aMHCR403Q mice studied,
the D0-6 treated mice had lower LV mass (Figure 3B,
FIGURE 3 Effects of Transgene Inhibition in Male tTA x aMHCR403Q Mice
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565Online Table 5). Although this ﬁnding was modestly
higher than LV mass in treated WT mice, there were
no differences between D0-6 treated mutant mice and
untreated tTA mice (p ¼ 0.29). Heart weight/
body weight ratio in D0-6 treated tTA x aMHCR403Q
mice was similar to that in D0-6 treated WT mice(Online Table 5) and untreated tTA mice (p ¼ 0.20).
Myocardial histopathological features were also bet-
ter preserved in D0-6 treated tTA x aMHCR403Q mice
than in vehicle-treated tTA x aMHCR403Q mice, with
less myoﬁbrillar disarray, less Z-disc misalignment,
and lower CVF (Figures 3F to 3H, Online Figure 2).
CENTRAL ILLUSTRATION LVH Reversibility Through Mutation-Silencing Therapy
In a double-transgenic mouse model, doxycycline administration was evaluated for its ability to inhibit expression of the hypertrophic
cardiomyopathy–causing Arg403Gln mutation in the a-myosin heavy chain gene. Doxycycline was given at 3 time points: 0 to 6 weeks, 6 to 40
weeks, and 20 to 40 weeks (the latter 2 groups representing early and established disease). Although transgene inhibition at 6 weeks reduced
ﬁbrosis, it did not prevent left ventricular hypertrophy (LVH) or functional changes; no effects were seen in the 20- to 40-week group. Disease
suppression was experienced only in the 0- to 6-week group treated from conception.
Cannon et al. J A C C V O L . 6 5 , N O . 6 , 2 0 1 5
Reversibility of LVH F E B R U A R Y 1 7 , 2 0 1 5 : 5 6 0 – 9
566DISCUSSION
We found that inhibiting expression of the mutant
aMHCR403Q transgene in adult tTA x aMHCR403Q mice
from 6 weeks (early disease) or 20 weeks (established
disease) had no effect on LVH remodeling, but
transgene inhibition from conception to 6 weeks had
protective effects. These observations suggest that
cardiomyocyte defects established very early in life
act as an inductive trigger for sustained LVH and have
important implications for the timing and efﬁcacy of
targeted mutation-silencing therapies.
To undertake these studies of LVH prevention and
reversal, we generated a novel mouse model in which
expression of an Arg403Gln a-MHC transgene could
be temporally regulated by doxycycline administra-
tion. The “gene on” tTA x aMHCR403Q mice showed
progressive LVH, disarray, and ﬁbrosis. These changes
replicate those seen in humans with HCM (1,2) and
in 2 other mouse models of Arg403Gln a-MHC gener-
ated by knock-in and transgenic approaches,respectively (4,7), as well as a rabbit Arg403Gln
b-MHC model (9).
Although all Arg403Gln MHC animal models dis-
played hallmark histopathological features of HCM,
there were some differences in LV dimensions and
functional parameters. LV systolic function in patients
with HCM is generally normal or hyperdynamic but
may become progressively impaired in patients with
end-stage disease (15). Age-related progression to DCM
has been noted in male single-transgenic Arg403Gln
a-MHC mice (8) and in Arg403Gln b-MHC rabbits (10),
whereas homozygous knock-in Arg403Gln a-MHC
mice have severe neonatal-onset DCM (6). Fulminant
postnatal DCM rather than HCM is also seen in
heterozygous knock-in Arg403Gln a-MHC mice when
they are crossed to transgenic mice with a troponin I
mutation (16). In tTA-regulated murine models, the
presence of the tTA transgene was reported to cause
mild cardiomyopathy in some studies but not others
(17,18). We found no differences in LVDD or LVFS
between 40-week-oldmale tTA andWTmice, a ﬁnding
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567indicating that the tTA transgene did not determine
the changes seen in these parameters in tTA x
aMHCR403Q mice. Similar to other Arg403Gln MHC
murine models (4,7), sex differences in LV functional
parameters were present in tTA x aMHCR403Q mice,
with male mice exhibiting relatively earlier and more
severe changes. Taken together, these observations
suggest that several factors, including mutant MHC
“dose,” age, sex, and background genetic context, can
modify Arg403Gln MHC LV phenotype.
Atrial dilation, present in male and female tTA x
aMHCR403Q mice from 12 weeks of age, has been
observed in human subjects with Arg403Gln b-MHC (19)
and in some animal models (4,10) but not others (7), and
it has numerous potential causes. Abnormalities of
diastolic relaxation commonly manifest in HCM and
precede hypertrophy development in humans and mice
(5,20), whereas elevatedﬁlling pressures can result from
severe systolic dysfunction or LV outﬂow tract obstruc-
tion. Interestingly, Arg403Gln MHC animal models
have a concentric pattern of LVH, and LV outﬂow
tract obstruction has not been described. Because
a-MHC is expressed in the fetal and adult atrium in
mice (11), a contribution of primary atrial myopathic
changes to atrial dilatation cannot be excluded.
HYPERTROPHY-MODIFYING INTERVENTIONS. Arg403
is situated in the myosin head at the base of a loop that
interacts with actin, and the Gln403 substitution at
this site increases actin-myosin sliding velocities,
adenosine triphosphate hydrolysis, and force genera-
tion (21). These changes are associated with increased
end-diastolic and end-systolic stiffness and slowed
relaxation dynamics of individual cardiomyocytes,
and they manifest as increased end-diastolic and end-
systolic chamber elastance and diastolic dysfunction
at the whole-heart level (22). The primary mutation-
induced defects trigger a cascade of downstream
effects including alterations in intracellular calcium
homeostasis, mitochondrial function, myocardial en-
ergetics, and cell signaling (1,2). Several interventions
that modify components of these hypertrophic re-
sponses have beneﬁcial effects in Arg403Gln murine
and rabbit models, including diltiazem (L-type calcium
channel inhibitor) (23), simvastatin and atorvastatin
(3-hydroxy-3-methylglutaryl–coenzyme A [HMG-CoA]
reductase inhibitors) (24,25), N-acetylcysteine (anti-
oxidant) (26), and exercise training (27).
Researchers have proposed that small molecules
designed to bind speciﬁcally to mutant myosin pro-
tein may directly target the sarcomeric defects un-
derpinning HCM and prevent disease onset (28). Jiang
et al. (12) provided proof of concept for mutation-
inhibitory therapies by demonstrating that allele-
speciﬁc RNAi-mediated silencing of Arg403Glna-MHC in 1-day-old mice prevented later develop-
ment of LVH, disarray, and ﬁbrosis. Notably, RNAi
was ineffective in mice with established disease.
Using a tTA-regulated gene expression system, we
found that LVH was unable to be prevented or
reversed by inhibiting an aMHCR403Q transgene from
6 weeks (early disease) or 20 weeks (established dis-
ease), respectively. The inability to induce disease
regression at these time points could not be explained
by effects of the tTA transgene or doxycycline’s fail-
ure to suppress expression of the aMHCR403Q trans-
gene adequately. We do not believe that persistent
expression of the mutant protein can explain our
ﬁndings, given that the reported turnover time (half-
life) of myosin is 1 to 12 days (29,30).
WHAT IS THE INDUCTIVE TRIGGER FOR SUSTAINED
LVH? In the embryonic mouse, the tubular heart
contains high levels of both a-MHC and b-MHC. As
chamber formation progresses, b-MHC becomes
restricted to the ventricles, where levels remain
high until birth, when there is a rapid fall (within
1 day). In the atria, a-MHC is expressed at high levels
throughout development and after birth. In the ven-
tricles, a-MHC is expressed at relatively lower levels
(up to 8-fold) than b-MHC from embryonic day 10.5
onward. However, immediately after birth, a-MHC
levels increase dramatically, and an a/b ratio of 16:1 is
maintained throughout adult life (11,31). Coinciding
with this isoform switch, the ventricular effects of the
aMHCR403Q transgene would be predominantly man-
ifest from the ﬁrst postnatal week onward, but they
could affect heart development.
One plausible hypothesis is that the combination of
WT and hypercontractile mutant MHC in cardiac sar-
comeres may result in heterogeneous force pro-
duction and profound changes in the mechanical
stresses within cardiomyocytes during critical periods
of maturation and growth. This could affect not only
the structural integrity of individual sarcomeres and
Z-discs but also myoﬁbril alignment, mitochondrial
surface tension and function, intercalated disc func-
tion, nuclear shape and function, and epigenetic state.
The “dose” of mutant protein is a further con-
sideration, andwe are unable to exclude the possibility
that transient high levels of the aMHCR403Q transgene
in mice could have deleterious effects not seen in
human heterozygous mutation carriers. Undoubtedly,
multiple factors are involved, and elucidation of
the full spectrum of developmental defects that
stimulate lifelong hypertrophic remodeling in HCM
remains an important avenue for future research.
IMPLICATIONS FOR TARGETED MUTATION-SILENCING
THERAPIES. The failure of aMHCR403Q transgene
inhibition to demonstrate preventive effects in
PERSPECTIVES
COMPETENCY INMEDICAL KNOWLEDGE:Muta-
tions ingenesencodingsarcomericproteinsplayacrucial
role in the pathogenesis of inherited forms of HCM.
COMPETENCY IN PATIENT CARE: Identifying the
genetic causesofHCM in families facilitatesprenatal and
early postnatal identiﬁcation of mutation carriers and
provides an opportunity for preventative therapies.
TRANSLATIONAL OUTLOOK: Mutation-silencing
interventions in genetically predisposed individuals
early in development could prevent HCM develop-
ment later in life, whereas regression of hypertrophy
in patients with established disease may be possible
by modifying downstream signaling pathways.
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5686-week-old tTA x aMHCR403Q mice implies that irre-
versible inductive stimuli for LVH are already estab-
lished by this age. Given that the most rapid period of
hypertrophic remodeling in patients with HCM is
typically seen during the pubertal growth spurt (32),
targeted mutation-silencing therapies may need to be
administered before adolescence to be effective.
Our data suggest that primary prevention of HCM
may be possible only when mutation-silencing thera-
pies are commenced in utero or in the early post-partum
period because protective effects were seen only in
tTA x aMHCR403Q mice that received doxycycline from
conception to 6 weeks of age. Given that b-MHC is the
predominant MHC isoform in human fetal and adult
ventricles (33), the effects of HCM-causing b-MHC mu-
tations could extend during an equivalent prenatal and
postnatal timespan. The demonstrated efﬁcacy of
RNAi-induced Arg403Gln b-MHC allelic silencing in
1-day-old mice (12) suggests that postnatal therapy
could be sufﬁcient to prevent HCM. Our group recently
described a thyroid hormone–mediated proliferative
burst in cardiomyocyte numbers at 15 days in pre-
adolescent mice (34). This period of accelerated
growth falls within the timeframe of successful
mutation-silencing in tTA x aMHCR403Q mice and
clearly does not mitigate against subsequent hypertro-
phy prevention. Further studies are clearly required to
deﬁne the therapeutic window for effective mutation-
silencing interventions in humans and mice more
closely. Identifying genetic causes of HCM in families
and prenatal or early postnatal genetic testing may be
necessary to identify individuals likely to beneﬁt from
these therapies, but it is hoped that intervention before
the pubertal cardiac growth spurt may be sufﬁcient.
STUDY LIMITATIONS. Due to genetic and species
differences, observations in double-transgenic tTA x
aMHCR403Q mice cannot be extrapolated directly to
humans with HCM, and further studies in patient
cohorts are warranted.
CONCLUSIONS
This study generated a regulatable double-transgenic
Arg403Gln a-MHC murine model of HCM. Inhibiting
expression of the aMHCR403Q transgene in mice withearly (6 weeks) or established disease (20 weeks)
does not prevent or reverse the extent of LVH present
at 40 weeks. In contrast, transgene inhibition from
conception up to 6 weeks provides a sustained pro-
tective effect (Central Illustration). These data suggest
that irreversible mutation-induced perturbations of
cardiomyocyte structure and function are established
in the postnatal period, and hence mutation-silencing
therapies for HCM prevention would need to be
administered very early to be effective.
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